In the latest round of Sanofi's bid to acquire Genzyme, unnamed leaks (er..sources) say that the company will either sweeten its $69 per share bid and offer no CVRs relative to Campath's performance, or will stick to its $69 per share bid and offer the CVR. It will not do both.
Bettors (er..analysts) seem to believe that Sanofi will stick with its $69 per share bid for right now, and simply extend this offer when its expiry comes due on December 10th. No deal appears imminent in 2010. See Fierce Biotech story.
Posted by Bruce Lehr December 7th 2010.